Progenics filing for constipation drug |
|
|
|
Published
:
Fri, 30 Mar 2007 14:03
|
NEW YORK (AP) - Drug developer Progenics Pharmaceuticals Inc. said it will submit a marketing application Friday with the Food and Drug Administration for a constipation treatment targeted toward people taking opiate painkillers.Progenics, which is partnering with Wyeth Pharmaceuticals on the drug, is applying for a form of methylnaltrexone that is administered just under the skin. Constipation occurs in most people who are prescribed opiate painkillers.The application will include data from two late-stage studies showing that methylnaltrexone significantly improved the constipation induced by opiate painkillers.If the drug is approved, Progenics and Wyeth plan to launch single-use vials of methylnaltrexone in early 2008, and pre-filled syringes later that year.Copyright 2007 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
|
|
|
|
|
|
|
| Stock
Quotes * |
|
NASDAQ
|
|
1599.06 |
-53.32 (
-3.29 %)
|
| SYMBOL (
2009-01-08 ) |
| LAST |
CHANGE
|
| SYMBOL (
2009-01-07 )
|
| LAST |
CHANGE
|
| SYMBOL (
2009-01-07 )
|
| LAST |
CHANGE
|
|
|
Print this Story
Wyeth, Progenics starting new study 